Shore Capital restated their buy rating on shares of Hargreaves Lansdown (LON:HL – Free Report) in a report published on Wednesday morning, Marketbeat reports.
A number of other equities research analysts also recently commented on HL. Barclays raised their target price on Hargreaves Lansdown from GBX 1,210 ($15.37) to GBX 1,250 ($15.88) and gave the company an overweight rating in a report on Wednesday, May 1st. Royal Bank of Canada reduced their target price on Hargreaves Lansdown from GBX 850 ($10.80) to GBX 825 ($10.48) and set a sector perform rating for the company in a report on Monday, February 26th. Jefferies Financial Group downgraded Hargreaves Lansdown to a hold rating and raised their target price for the company from GBX 1,035 ($13.15) to GBX 1,140 ($14.49) in a report on Wednesday. Finally, Canaccord Genuity Group raised their target price on Hargreaves Lansdown from GBX 1,148 ($14.59) to GBX 1,342 ($17.05) and gave the company a buy rating in a report on Monday, June 3rd. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Hargreaves Lansdown currently has an average rating of Hold and an average target price of GBX 1,008.83 ($12.82).
Get Our Latest Stock Analysis on HL
Hargreaves Lansdown Price Performance
About Hargreaves Lansdown
Hargreaves Lansdown plc provides investment services for individuals and corporates in the United Kingdom and Poland. The company offers stocks and shares individual savings accounts (ISAs), fund and share accounts, and junior and lifetime ISAs. It also provides pension services, including self-invested personal pensions (SIPP), junior SIPPs, annuities, and drawdown; share dealing services; fund dealing; and cash management services.
Read More
- Five stocks we like better than Hargreaves Lansdown
- Insider Selling Explained: Can it Inform Your Investing Choices?
- McDonald’s Stock: Balancing Value and Innovation
- Earnings Per Share Calculator: How to Calculate EPS
- MarketBeat Week in Review – 6/17 – 6/21
- Energy and Oil Stocks Explained
- Sarepta Therapeutics Stock Soars on FDA Approval
Receive News & Ratings for Hargreaves Lansdown Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hargreaves Lansdown and related companies with MarketBeat.com's FREE daily email newsletter.